LIFECORE BIOMEDICAL, INC. Excess Tax Benefit from Share-based Compensation, Financing Activities
LIFECORE BIOMEDICAL, INC. (LFCR) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $150.00 thousand for the 12-month period ending 2016-05-29, per its 10-K filed 2016-08-01.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2016-08-01
- LIFECORE BIOMEDICAL, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-05-29 was $17.00K, a 90.86% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-02-28 was $43.00K, a 82.16% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2015-11-29 was $16.00K.
- LIFECORE BIOMEDICAL, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2015-08-30 was $74.00K.
- LIFECORE BIOMEDICAL, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2016 was $150.00K, a 67.60% decline from fiscal 2015.
- LIFECORE BIOMEDICAL, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $463.00K, a 75.91% decline from fiscal 2014.
- LIFECORE BIOMEDICAL, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2014 was $1.92M, a 47.62% increase from fiscal 2013.
- LIFECORE BIOMEDICAL, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2013 was $1.30M, a 67.91% decline from fiscal 2012.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|---|
| 2016-05-29 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-01 | $60.00K derived: sum of 2 quarters · filed 2016-08-01 | $76.00K derived: sum of 3 quarters · filed 2016-08-01 | $150.00K 10-K · filed 2016-08-01 |
| 2016-02-28 | $43.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-03-30 | $59.00K derived: sum of 2 quarters · filed 2016-03-30 | $133.00K 10-Q · filed 2016-03-30 | $319.00K derived: sum of 4 quarters · filed 2016-08-01 |
| 2015-11-29 | $16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-01-07 | $90.00K 10-Q · filed 2016-01-07 | $276.00K derived: sum of 3 quarters · filed 2016-08-01 | $517.00K derived: sum of 4 quarters · filed 2016-08-01 |
| 2015-08-30 | $74.00K 10-Q · filed 2015-10-01 | $260.00K derived: sum of 2 quarters · filed 2016-08-01 | $501.00K derived: sum of 3 quarters · filed 2016-08-01 | |
| 2015-05-31 | $186.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-01 | $427.00K derived: sum of 2 quarters · filed 2016-08-01 | $463.00K 10-K · filed 2016-08-01 | |
| 2015-03-01 | $241.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-03-30 | $277.00K 10-Q · filed 2016-03-30 | ||
| 2014-11-30 | $36.00K 10-Q · filed 2016-01-07 | |||
| 2014-05-25 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-01 | $1.75M derived: sum of 2 quarters · filed 2016-08-01 | $1.92M 10-K · filed 2016-08-01 | |
| 2014-02-23 | $1.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-04-02 | $1.91M 10-Q · filed 2015-04-02 | ||
| 2013-11-24 | $175.00K 10-Q · filed 2015-01-09 | |||
| 2013-05-26 | -$1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2015-07-31 | -$512.00K derived: sum of 2 quarters · filed 2015-07-31 | $797.00K derived: sum of 3 quarters · filed 2015-07-31 | $1.30M 10-K · filed 2015-07-31 |
| 2013-02-24 | $929.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-03-28 | $2.24M derived: sum of 2 quarters · filed 2014-03-28 | $2.74M 10-Q · filed 2014-03-28 | $1.29M derived: sum of 4 quarters · filed 2014-08-01 |
| 2012-11-25 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-01-03 | $1.81M 10-Q · filed 2014-01-03 | $360.00K derived: sum of 3 quarters · filed 2014-08-01 | $2.49M derived: sum of 4 quarters · filed 2014-08-01 |
| 2012-08-26 | $505.00K 10-Q · filed 2013-09-26 | -$949.00K derived: sum of 2 quarters · filed 2014-08-01 | $1.18M derived: sum of 3 quarters · filed 2014-08-01 | $3.28M derived: sum of 4 quarters · filed 2014-08-01 |
| 2012-05-27 | -$1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-01 | $679.00K derived: sum of 2 quarters · filed 2014-08-01 | $2.78M derived: sum of 3 quarters · filed 2014-08-01 | $4.06M 10-K · filed 2014-08-01 |
| 2012-02-26 | $2.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-04-04 | $4.23M derived: sum of 2 quarters · filed 2013-04-04 | $5.51M 10-Q · filed 2013-04-04 | $4.26M derived: sum of 4 quarters · filed 2013-08-07 |
| 2011-11-27 | $2.10M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2013-01-04 | $3.38M 10-Q · filed 2013-01-04 | $2.13M derived: sum of 3 quarters · filed 2013-08-07 | |
| 2011-08-28 | $1.28M 10-Q/A · filed 2013-01-02 | $27.00K derived: sum of 2 quarters · filed 2013-08-07 | ||
| 2011-05-29 | -$1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2013-08-07 | $764.00K 10-K · filed 2013-08-07 | ||
| 2011-02-27 | $2.02M 10-Q · filed 2012-03-28 | |||
| 2010-11-28 | $1.58M 10-Q · filed 2012-01-05 | |||
| 2010-08-29 | $804.00K 10-Q · filed 2011-10-05 | |||
| 2010-05-30 | $517.00K 10-K · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |